Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.
While already established as a world-leading preclinical CRO specialized in humanized-mice models for in vivo pharmacology, this additional capital brought by Cathay Capital – paired with investments from TransCure’s management team and Financière Arbevel – is set to further accelerate the already-sustained growth and global expansion of the biopharmaceutical player over the coming years.
How did Larka support Cathay Capital’s Investment Process?
This Commercial Due Diligence provided Cathay Capital with key insights and recommendations, giving Larka a decisive role in the overall decision-making process, and in turn, the upcoming investment of the Franco-Chinese Private Equity firm in TransCure.
“We are delighted to be part of TransCure’s exciting and ambitious development plan. During the process, Larka was both reactive and available for the team. Its contribution and deep healthcare knowledge have proven key for us in our understanding of TransCure’s unique proposition and building our strong conviction about the company”
Fabien Wesse - Managing Partner at Cathay Capital
As for all of the M&A services provided by Larka to Private Equity firms, this Commercial Due Diligence process leveraged our teams’ extensive life sciences industry and biopharmaceuticals knowledge – and in this case the Drug Discovery universe and humanized-mice models – to provide Cathay with a comprehensive picture of TransCure’s:
- Services and core value proposition within the drug discovery landscape
- Humanized-mice CRO market dynamics & market value
- Positioning in the competitive landscape
- Customer environment and market feedbacks
- Business Plan review and growth avenues
What’s Next for TransCure bioServices?
Thanks to a unique set of capabilities combining deep scientifical knowledge, proprietary humanization technologies and a track-record of data accumulated over the past decade, the Archamps-based player has become a well-established specialized partner within the rapidly growing preclinical market.
Offering its highly competitive services to a number of Big Pharma and Biotech companies around the globe, the French CRO has experienced a double digit organic growth over the past 5 years, reaching over € 10Mn in annual revenues.
An impressive success, that lies in TransCure’s ability to develop and leverage best-in-class mice models of fully reconstituted human immune system (HIS) or human-liver (Hu-liver) with humanization rates that overperform market standards. Said advanced preclinical in vivo pharmacology with humanized-mice models enable TransCure and the biopharmaceutical companies it serves to address several critical therapeutic areas, including:
- Immuno-oncology
- Infectious diseases
- Inflammatory auto-immune diseases
With Cathay’s upcoming strategic and financial support, coupled with its strong healthcare experience and global platform, TransCure bioServices will be able to initiate its next phase of development and further consolidate its position as a leading one-stop-shop preclinical CRO by:
- Accelerating its global expansion
- Developing new mice model platforms
- Increasing its production capacities
- Strengthening the currently 80 FTE team
- Executing a focused external growth strategy
Read our latest M&A transaction news
About Cathay Capital, the Private Equity Firm Advised:
Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $4.5 billion in assets, has completed over 220 buyouts, growth and venture capital investments with the global reach and local expertise from offices in Paris, New York, Shanghai, Munich, San Francisco, Beijing, Singapore, Shenzhen and Tel Aviv.
About TransCure bioServices, the Contract Research Organization Target:
TransCure bioServices SAS is a European CRO based in France offering preclinical predictive in vivo pharmacology testing services to international large pharmaceutical, biotech and academic customers. Uniquely designed preclinical models with functional human immune system and human hepatocytes/liver provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV, Dengue), liver diseases, vaccines, and immuno-hepato toxicity (DMPK, ADME). If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver.